Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

(Reuters) -Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder ...